Business Wire - Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN® Superior to Lipitor in Reducing LDL "Bad" Cholesterol in Patients with Type…
Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J. — Results from a clinical study conducted in 1,229 patients with type II diabetes mellitus and high cholesterol showed that VYTORIN (ezetimibe/simvastatin) provided superior reduction in LDL “bad” cholesterol compared to Lipitor([R]) (atorvastatin) at the dose comparisons studied, according to data published in the December 2006 issue of Mayo Clinic Proceedings. The primary efficacy endpoint was the percent change from baseline in LDL cholesterol at the end of the six-week treatment period.
Related Results
CORRECTIONS/CLARIFICATIONS
WALL STREET CHOICE: BEATING GUIDANCE WITH NEW DRUGS AND LOWER COSTS
Merck and Schering-Plough's statin combo hits pharmacies
New Study Showed VYTORIN Significantly More Effective than Crestor…
Vytorin study raises questions about Cholesterol’s Import
VYTORIN, which contains ezetimibe and simvastatin, is the first and only product approved to treat the two sources of cholesterol by inhibiting the production of cholesterol in the liver and blocking the absorption of cholesterol in the intestine, including cholesterol from food. VYTORIN is marketed as INEGY in many countries outside the U.S.
VYTORIN 10/20 mg demonstrated a 53.6 mean percent reduction from baseline in LDL cholesterol as compared to a 38.3 percent reduction observed with Lipitor 10 mg and a 44.6 percent reduction with Lipitor 20 mg - the recommended usual starting doses of both agents. At the next highest doses, VYTORIN 10/40 mg decreased LDL cholesterol significantly more than Lipitor 40 mg — 57.6 percent compared to 50.9 percent, respectively, (p
